Renal effects of angiotensin converting enzyme inhibitors in heart failure: a clinician's guide to minimizing azotemia and diuretic-induced electrolyte imbalances.
Angiotensin converting enzyme (ACE) inhibitors have proved to be valuable, life-saving medications in the management of heart failure. While reducing myocardial oxygen consumption, they increase cardiac output and thus renal plasma flow. Despite reports in the literature of adverse effects of these drugs on renal function, the risks of functional deterioration are predictable in patient populations and remediable. Patients at greatest risk of declining renal function during therapy with ACE inhibitors are those in whom maintenance of renal function is dependent on angiotensin II. Reducing the dose of the concomitant diuretic, liberalizing the dietary intake of sodium, and increasing the dose of the ACE inhibitor usually restores renal function to baseline. In patients with severe renal insufficiency, reducing the dose of the ACE inhibitor might be necessary to preserve the glomerular filtration rate.
Weinberg
M S
MS
Roger Williams Medical Center, Brown University School of Medicine, REN Center, Providence, Rhode Island.
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D048909:Diabetes Complications; D004232:Diuretics / Q000009:adverse effects; D004656:Enalapril / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007668:Kidney / Q000187:drug effects* / Q000503:physiopathology; D012084:Renin-Angiotensin System / Q000502:physiology; D012307:Risk Factors; D012982:Sodium, Dietary; D014511:Uremia / Q000139:chemically induced; D014883:Water-Electrolyte Imbalance / Q000139:chemically induced / Q000503:physiopathology
D000806:Angiotensin-Converting Enzyme Inhibitors; D004232:Diuretics; D012982:Sodium, Dietary; D004656:Enalapril